Cymabay Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. It is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
Buy US stocks in Australia starting with CBAY. Open an account and start investing today!
Ready to start your investing journey with Stake?Open an account
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CBAY
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in CBAY
Buy CBAY from US$3 brokerage
Invest in 6,000+ U.S. stocks and ETFs
Own a slice of CBAY from only US$10 with fractional shares